Formulary decision-making considerations: COX-2 inhibitiors

Managed Care Interface

Volumn 17, Issue 11, 2004, Pages

  Shaya, Fadia T ^a   Wong, Winston ^b   Shin, James Y ^a   Martin, Lee Ann ^b   Samant, Navendu D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b CareFirst BlueCross BlueShield ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DEXTROMETHORPHAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUCONAZOLE; FUROSEMIDE; IBUPROFEN; KETOCONAZOLE; LITHIUM; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; ROFECOXIB; VALDECOXIB; WARFARIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANEMIA; CLINICAL TRIAL; DECISION MAKING; DEMOGRAPHY; DIGESTIVE SYSTEM ULCER; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; ECONOMIC ASPECT; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; KIDNEY NECROSIS; NEPHROTOXICITY; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH PERFORATION; ARTICLE; DRUG INTERACTION; HEALTH INSURANCE; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PAIN; PRACTICE GUIDELINE; PUBLICATION; TREATMENT OUTCOME; UNITED STATES;

CYCLOOXYGENASE INHIBITORS; DECISION MAKING, ORGANIZATIONAL; DRUG INTERACTIONS; FORMULARIES; HUMANS; MANAGED CARE PROGRAMS; PAIN; PRACTICE GUIDELINES; TREATMENT OUTCOME; UNITED STATES;

EID: 14944367266     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Lyles A: Decision-makers' use of pharmacoeconomics: What does the research tell us? Expert Rev Pharmacoeconomics Outcomes Res 2001;1:133-144.
2. Fullerton DSP, Atherly DS: Formulary development at Regence BlueShield - a formula for success. Presented at the sixth annual International Society for Pharmacoeconomic Outcomes Research meeting. Arlington, VA, May 23, 2001.
3. McCain J: System helps P&T committees get pharmacoeconomics data they need. Manag Care 2001;10(4):52-55.
4. Sullivan SD, Lyles A, Luce B, et al: AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. JMCP 2001;7:272-282.
5. Goldenberg MM: Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther 1999;21:1497-1513.
6. Scott LJ, Lamb HM: Rofecoxib. Drugs 1999;58:499-505.
7. Bensen WG, Fiechtner JJ, McMillen JI, et al: Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized, controlled trial. Mayo Clin Proc 1999;74:1095-1105.
8. Von Scheele B, Pena B, Wong J, et al: Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. Rheumatology 2003;42(suppl 3):53-59.
9. Silverstein FE, Faich G, Goldstein JL, et al: Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The Celecoxib Long-term Arthritis Safety Study (CLASS) - a randomized controlled trial. JAMA 2000;284:1247-1255.
10. Bombardier C, Laine L, Reicin A, et al, for the VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2001;343:1520-1528.
11. Schwartz JI, Vandormael K, Malice MP, et al: Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002; 72:50-61.
12. Spiegel BM, Targownik L, Dulai GS, et al: The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003;138:795-806.
13. Metcalfe S, Dougherty S, McNee W: Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis: Celecoxib's relative gastrointestinal safety overstated. BMJ 2003;326:334.
14. Topics: celecoxib and rofecoxib. Food and Drug Administration (www.accessdata.fda.gov/scripts/cder/drugsatfda/), Oct. 12, 2004.
15. Brown D: Promise and peril of Vioxx cast harsher light on new drugs. Washington Post October 3, 2004; A14.
16. Malmstrom K, Daniels S, Kotey P, et al: Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther 1999;21:1653-1663.
17. Vioxx product information, in Physicians' Desk Reference. Montville, NJ, Medical Economics Co., 2003.
18. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
19. Simon LS, Weaver AL, Graham DY, et al: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999;282:1921-1928.
20. Day R, Morrison B, Luza A: A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs. ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-1787.
21. Gimbel JS, Brugger A, Zhao W, et al: Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 2001;23:228-241.
22. American College of Rheumatology Subcommittee on Rheumatoid Arthritis: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46: 328-346.
23. American College of Rheumatology Subcommittee on Osteoarthritis: Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000;43: 1905-1915.
24. Merck announces voluntary worldwide withdrawal of Vioxx (press release). Merck & Co. (www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp), September 2004.
25. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-959.
26. Whelton A, Fort JG, Puma JA, et al, for the SUCCESS VI Study Group: Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
27. Jancin B: Cost of COX-2 inhibitors offset by decline in GI procedures. Family Practice News 2001;31(4):27.
28. Fendrick AM: Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy. Cleve Clin J Med 2002;69(suppl 1):I59-64.
29. Atherly DE, Fullerton DS, Sturm LI, et al: Cost impact of COX-2 inhibitors in a managed care plan: Implications for formulary decision-making. Value Health 2001;4:71-72.
30. Harley C, Wagner S: Switching and persistency in a NSAID and COX-2 inhibitor user population in managed care. Presented at the seventh annual International Society for Pharmacoeconomic Outcomes Research meeting. Arlington, VA, May 30, 2002.
31. Yu WM, Kiang G, Etemand LR: Utilization characteristics of COX-2 inhibitors in a large managed care health plan. Presented at the seventh annual International Society for Pharmacoeconomics and Outcomes Research. Arlington, VA, May 30, 2002.
32. Titlow K, Randel L, Clancy CM, et al: Drug coverage decisions: The role of dollars and values. Health Aff 2000;19(2): 240-247.
33. Lichtenstein DR, Wolfe MM: COX-2 selective NSAIDs: New and improved? JAMA 2000;284:1297-1299.
34. Franks P, Cameron C, Bertakis KD: On being new to an insurance plan: Health care use associated with the first years in a health insurance plan. Ann Fam Med 2003;1:156-161.
35. COX-2s lose favor. Managed Care (www.managedcaremag.com/archives/0304/ 0304.formulary.html), Oct. 14, 2004.
36. Preferred drug list. CareFirst BlueCross BlueShield (notesnet.carefirst. com/formulary/formulary.nsf/vwprintcode/print?Opendocument), January 1, 2004.
37. 2004 AdvancePCS drug list. AdvancePCS (www.advancerx. com/Formulary/pdl/2004/PDL.pdf), October 2004.
38. Three-tier drug list. Health First Health Plans, (www.health-first.org/ health_plans/commercial_hmo/3_tier_drug_list_2004. pdf) January 1, 2004.
39. Common non-preferred drugs & their preferred drug alternatives. Southern Health (www.southernhealth.com/content/items/9562/DrugAlternatives.pdf) , March 2004.
40. Shaya FT, Mullins CD, Wong W: Incidence versus prevalence modeling in pharmacoeconomics. Expert Rev Pharmacoeconomics Outcomes Res 2002;2:435-442.
41. Celebrex product information, in Physicians' Desk Reference. Montville, NJ, Medical Economics Co, 2003.
42. Bextra product information, in Physicians' Desk Reference. Montville, NJ, Medical Economics Co, 2003.
43. Geba GP, Weaver AL, Polis AB, et al, for the Vioxx, Acetaminophen, Celecoxib Trial (VACT) Group: Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee. JAMA 2002;287:64-71.
44. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.